RECETOX Přírodovědecké Fakulty Masarykovy Univerzity
Daiichi Sankyo Europe
FP7 Health
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
Mark Lawler, Bryan T. Hennessy, Federica Di Nicolantonio, Francesca Aroldi et al.
Citations
3 citations
Journal
BJC Reports
Topics
Colorectal Cancer Treatments and Studies
Field-Weighted Citation Impact (FWCI)
3.14
article
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
Mark Lawler, Bryan T. Hennessy, Federica Di Nicolantonio, Francesca Aroldi, Ruth Boyd, Corran Roberts, Josep M. Tabernero, Sandra Van Schaeybroeck, Richard Adams, Hajrah Khawaja, Jennifer Houlden, Julien Taı̈eb, Marc Peeters, Élena Elez, Jurgen Del‐Favero, Margaret Grayson, Manuel Salto‐Tellez, Linda Collins, Hans Prenen, Robin L. Jones, Richard H. Wilson, Géraldine Perkins, Robbie Carson, Vlad Popovici, Alberto Bardelli, Karolien Bettens, Vicky M. Coyle, Christian Diego Rolfo, Peter F. Gallagher, Thierry André, Tim Maughan, Pierre Laurent‐Puig, Mark R. Middleton
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
BJC ReportsVol. 3(1)
Institutions
Queen's University Belfast (GB), Belfast Health and Social Care Trust (GB), Royal College of Surgeons in Ireland (IE), University of Liverpool (GB), University of Antwerp (BE), Inserm (FR), Université Paris Cité (FR), Masaryk University (CZ), Velindre NHS Trust (GB), Nuffield Orthopaedic Centre (GB), Sorbonne Université (FR), University of Oxford (GB), Centre de Recherche des Cordeliers (FR), Assistance Publique – Hôpitaux de Paris (FR), Agilent Technologies (Belgium) (BE), Antwerp University Hospital (BE), Hôpital Européen Georges-Pompidou (FR), Hôpital Saint-Antoine (FR), IFOM (IT), Université Bourgogne Franche-Comté (FR), Vall d'Hebron Hospital Universitari (ES), Candiolo Cancer Institute (IT), University of Turin (IT), Cardiff University (GB)
Funders
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Merck KGaA, Les Laboratories Pierre Fabre, Seagen, Cancer Research UK, National Institute for Health and Care Research, University of Oxford, European Commission, Queen's University Belfast, Ministerstvo Školství, Mládeže a Tělovýchovy, Queen's University, Associazione Italiana per la Ricerca sul Cancro, Servier, Aptitude Health, Genentech, Samsung, Chugai Pharmaceutical, Takeda Oncology, RECETOX Přírodovědecké Fakulty Masarykovy Univerzity, Daiichi Sankyo Europe, FP7 Health